Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

Table 2 Treatment exposure in the safety population

Characteristic	FOLFOX6 plus cetuximab (arm A, n = 77)	FOLFIRI plus cetuximab (arm B, n = 74)
Exposure to cetuximab (Q1-Q3)
Median duration, wk	28.0 (17-46)	29.1 (13-46)
Median number of infusions	26.0 (14-40)	26.0 (12-42)
Relative dose intensity, n (%)
Only initial dose	4 (5)	3 (4)
< 60%	2 (3)	3 (4)
60% to < 80%	15 (19)	8 (11)
80% to < 90%	21 (27)	20 (27)
≥ 90%	35 (45)	40 (54)
Exposure to chemotherapy (Q1-Q3)
Median duration, wk	25.1 (19-28)	25.5 (14-28)
Median number of cycles	12 (7-12)	12 (6-12)
Relative dose intensity, n (%)
Oxaliplatin
No dose	1 (1)	74 (100)
< 60%	4 (5)	-
60% to < 80%	24 (31)	-
80% to < 90%	22 (29)	-
≥ 90%	26 (34)	-
Irinotecan
No dose	77 (100)	2 (3)
< 60%	-	3 (4)
60% to < 80%	-	18 (24)
80% to < 90%	-	13 (18)
≥ 90%	-	38 (51)
Bolus 5-FU
No dose	1 (1)	2 (3)
< 60%	1 (1)	2 (3)
60% to < 80%	28 (36)	19 (26)
80% to < 90%	19 (25)	14 (19)
≥ 90%	28 (36)	37 (50)
Continuous infusion 5-FU
No dose	1 (1)	2 (3)
< 60%	1 (1)	3 (4)
60% to < 80%	21 (27)	14 (19)
80% to < 90%	13 (17)	11 (15)
≥ 90%	41 (53)	44 (59)
Dose reductions1, n (%)
Cetuximab	9 (12)	5 (7)
Chemotherapy	25 (32)	17 (23)
Treatment delays1, n (%)
Any cetuximab
≥ 3 d	59 (77)	47 (64)
≥ 16 d	12 (16)	8 (11)
Any chemotherapy
≥ 3 d	59 (77)	51 (69)
≥ 14 d	25 (32)	15 (20)
Treatment discontinuation1, n (%)
Cetuximab	13 (17)	9 (12)
Chemotherapy	9 (12)	4 (5)

¹Dose reductions, treatment delays and discontinuations due to adverse events.